(Laval, Québec, Canada, November 20, 2014) – Altasciences is pleased to announce the opening of Algorithme Pharma USA, further expanding the Company’s North American footprint and ability to provide comprehensive Bioequivalence and Phase I/IIa clinical drug development capabilities in the United States.
Based in Fargo, North Dakota, Algorithme Pharma USA will focus on conducting Bioequivalence and Bioavailability trials, and will represent an extension of Algorithme Pharma, an Altasciences full service early stage clinical CRO in Montreal with more than 20 years of experience. Clients will benefit from a full-range of support services, including Bioanalysis, Data Management, Biostatistics, Regulatory Support, Clinical Pharmacology and Project Management.
Dr. Jim Carlson and his team at Algorithme Pharma USA are recognized industry leaders in the successful conduct of early development clinical trials. Pioneers in early phase research, they have conducted more than 20,000 clinical pharmacology studies in a variety of therapeutic areas such as asthma, allergies, dermatology and diabetes. They are renowned in the Bioequivalence sector by large pharmaceutical and biotechnology clients for their focus on operational excellence and individual customer service.
“Based on feedback from our US client base, it has been an objective of ours to expand into the US to provide additional options for accelerated study start-ups, studies with controlled substances and studies requiring more than one clinical site. The site in Fargo provides us with a unique opportunity to leverage the expertise of a highly qualified team that matches Altasciences’ philosophy of offering excellence in customer service and the best quality early stage clinical development services.” — Chris Perkin, Chief Executive Officer
Altasciences, owned by Kilmer Capital Partners, owns Algorithme Pharma, Algorithme Pharma USA and Vince and Associates Clinical Research. All organizations operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.
Altasciences, through its group of companies, provides comprehensive early stage clinical drug development services in Phase I/ IIa, including the necessary support services in this critical stage of drug development.
Leveraging the extensive expertise and capabilities within the group, the strategy is to maintain the core competencies and identity of each company and ensure that they benefit from the value of being part of a common larger organization focused on excellence in customer service, operating under the ALTASCIENCES banner.
About Kilmer Capital Partners
Kilmer Capital Partners is a leader in making private equity investments in mid-sized businesses undergoing periods of rapid growth, significant change or ownership transition. The Principals of Kilmer Capital have the strategic, operational, acquisition and financial expertise and experience to assist management teams in achieving their strategic visions.
FOR MORE INFORMATION